Syed Ali-Aamir Rizvi - 01 Apr 2024 Form 4 Insider Report for Poseida Therapeutics, Inc.

Role: Chief Medical Officer
Signature: /s/ Harry J.Leonhardt, Attorney-in-Fact
Issuer symbol: N/A
Transactions as of: 01 Apr 2024
Net transactions value: $0
Form type: 4
Filing time: 03 Apr 2024, 16:03:59 UTC
Previous filing: 23 Feb 2023
Next filing: 08 Jan 2025
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	PSTX	Common Stock	Award	$0	+185,000		$0.000000	185,000	01 Apr 2024	Direct	F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	PSTX	Employee Stock Option (Right to Buy)	Award	$0	+250,000		$0.000000	250,000	01 Apr 2024	Common Stock	250,000	$3.10	Direct	F2

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Represents shares issuable upon the vesting of restricted stock units granted pursuant to the Issuer's 2022 Inducement Plan. The RSUs are scheduled to vest in four equal annual installments.
F2	12.5% of the shares subject to the stock option will vest and become exercisable on the six-month anniversary of the grant date, and the remaining shares will vest in 42 equal monthly installments thereafter.